We report significant inverse associations between TSH concentrations and serum measurements of ∑PBDEs and BDEs 28, 47, 99, 100, and 153 in pregnant women. The odds of subclinical hyperthyroidism were also elevated in relation to ∑PBDEs and BDEs 100 and 153. Associations appeared to be primarily due to a decrease in TSH in participants in the highest quartile of PBDE serum concentrations. Relationships between ∑PBDEs and individual PBDE congeners and free T4 were generally null, and associations with total T4 were mostly inverse, but none were statistically significant.
This is the largest study to investigate associations between PBDEs and TH serum concentrations in pregnant women. Only one small study (
n = 9) previously examined the question and found no association between the sum of BDEs 47, 99, 100, 153, 154, and 183 and free or total T
4 but did not measure TSH (
Mazdai et al. 2003). Contrary to most studies conducted in nonpregnant adults (
Bloom et al. 2008;
Dallaire et al. 2009;
Turyk et al. 2008), we did not find positive trends between PBDE exposure and free T
4. Although this discrepancy may be explained in part by differences in the methods used to measure free T
4 by prior studies (immunoassays) relative to the present study (direct equilibrium dialysis), elevated free T
4 suggests that exposure to PBDE may have a hyperthyroidic effect, which is consistent with our results of decreased TSH. For the most part, previous studies of nonpregnant adults did suggest reduced TSH serum concentrations in relation to higher PBDE exposure (
Bloom et al. 2008;
Dallaire et al. 2009;
Hagmar et al. 2001;
Turyk et al. 2008). Lending support to our results, a recent study (
Turyk et al. 2008) found that men with ∑PBDEs > 95th percentile (193 ng/g lipids) had substantially increased odds of having detectable serum thyroglobulin antibodies (OR = 6.1; 95% CI, 1.9–19.2), which are found in 80% of Graves disease patients (
Weetman 2000). Graves disease is believed to be the major cause of hyperthyroidism during pregnancy, accounting for > 85% of cases, and may play a role in subclinical hyperthyroidism (
Glinoer 1997;
Mestman 1997).
It is unclear whether low maternal TSH affects fetal health because
in vitro studies suggest that human placental permeability to TSH is limited (
Bajoria and Fisk 1998). Only one study has investigated the relation between maternal subclinical hyperthyroidism and adverse pregnancy outcomes in humans (
Casey et al. 2006). The authors found no increase in low birth weight, major malformations, or fetal, neonatal, or perinatal mortality in infants of 433 women with TSH levels ≤ 2.5th percentile for gestational age and nonelevated free T
4 levels (≤ 1.75 ng/dL) relative to 23,124 women with normal TSH levels. Nevertheless, subclinical hyperthyroidism may lead to clinical hyperthyroidism (
Surks et al. 2004), and hyperthyroidism during pregnancy has been linked with increased risks of miscarriage, premature birth, and intrauterine growth retardation (
Lazarus 2005). No studies have investigated the latent effects on subsequent child health or development.
Evans et al. (2002), however, reported that brain neuronal and glial cell differentiation is affected in offspring of partially thyroidectomized rats rendered moderately hyperthyroidic by daily infusion of T
4, suggesting that maternal hyperthyroidism may affect fetal neurodevelopment.
There are no data regarding associations between subclinical hyperthyroidism during pregnancy and maternal health, although clinical hyperthyroidism has been related to preeclampsia (
Millar et al. 1994). It is also unclear whether thyroid dysfunction during pregnancy is related to pre- or postpartum TH status. In the nonpregnant state, however, depressed TSH suggests that a woman’s free T
4 and/or T
3 is above her own individual set point, which can be indicative of mild thyroid failure (
Andersen et al. 2003). Studies conducted in nonpregnant adults report that subclinical hyperthyroidism may be associated with all-cause mortality, cardiovascular mortality, cardiac dysfunction, reduced bone mineral density, and increased fracture risk (
Surks et al. 2004).
The present study has a number of strengths. We used state-of-the-art methods to measure TH, including equilibrium dialysis for free T4 and an ultrasensitive third-generation assay with low LODs to measure TSH. We also had information on a large number of potential confounders, including demographic characteristics and environmental exposures to other endocrine disruptors such as lead, PCBs, and organochlorine pesticides. In addition, these results were unchanged after the exclusion of outliers and were robust to the lipid-adjustment method and to the summation method for ∑PBDEs (weight or molar basis).
The strong correlation among PBDE congeners, however, hampered our ability to distinguish their independent association, and the cross-sectional nature of this study limits causal inference. Reverse causation, for instance, cannot be excluded because TH regulates a number of metabolic pathways, including lipid metabolism and the activity of some cytochrome P450 enzymes (
Takahashi et al. 2010;
Yen 2005), which may alter PBDE serum concentrations. In addition, the mechanism of action for reduced TSH has not been clearly established. Possibly because of their structural similarity with T
4 and T
3, hydroxylated PBDEs (OH-PBDEs) have been shown to bind to thyroid receptors α1 and β and may thus inhibit the release of TSH by the pituitary (
Marsh et al. 1998). Exposure of human hepatocytes to BDE-99
in vitro has also been shown to up-regulate type I deiodinase, which is involved in the deiodination of T
4 to T
3 and reverse-T
3 (
Stapleton et al. 2009). Elevated T
3 would result in decreased TSH levels, but we did not measure T
3 in this study because of limited sample volume. In addition, other chemicals have been shown to lower TSH through binding to the retinoid X receptor or interference with neuroendocrine signaling pathways (
Haugen 2009), but few studies have investigated whether PBDEs act through these mechanisms.
It is noteworthy that studies conducted in rodents generally reported a hypothyroxinemic effect of exposure to PBDEs whereas human studies suggest a hyperthyroidic effect. Discrepancies between human and animal studies may be due to the high doses used in animal studies and physiologic differences. For instance, OH-PBDEs have been shown to competitively bind to human transthyretin (TTR), possibly resulting in increased T
4 clearance (
Meerts et al. 2000). Although TTR binds 75% of the circulating T
4 in rats (
Chanoine et al. 1992), it only binds 10–15% in humans (
Robbins 2000), and thus effects of PBDEs through this mechanism may be stronger in rats than in humans. Animal studies have also reported that the PBDE commercial mixtures DE-71, DE-79, and Bromkal 70-5DE induce UDP-GT (
Hallgren et al. 2001;
Zhou et al. 2001), which catalyzes the glucuronidation of T
4, the rate-limiting step in T
4 elimination. It is, however, unclear whether PBDEs induce UDP-GT in humans.